UBS Group Issues Pessimistic Forecast for Kenvue (NYSE:KVUE) Stock Price

Kenvue (NYSE:KVUE) had its price objective decreased by stock analysts at UBS Group from $19.00 to $18.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group’s target price indicates a potential upside of 7.63% from the company’s previous close.

Several other equities research analysts have also issued reports on KVUE. Canaccord Genuity Group upped their price target on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research report on Wednesday, February 18th. Jefferies Financial Group lowered Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the company from $23.00 to $18.00 in a research report on Friday, January 30th. Barclays upped their price target on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Friday, March 6th. Argus raised Kenvue to a “hold” rating in a research report on Friday, March 6th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a research report on Friday, January 9th. Three equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus target price of $19.50.

Kenvue Stock Down 3.3%

Shares of Kenvue stock traded down $0.58 on Tuesday, hitting $16.72. 15,529,809 shares of the company’s stock traded hands, compared to its average volume of 39,994,559. The stock has a market cap of $32.06 billion, a P/E ratio of 21.66, a PEG ratio of 3.89 and a beta of 0.61. The company has a quick ratio of 0.68, a current ratio of 0.96 and a debt-to-equity ratio of 0.66. The firm’s 50-day moving average is $17.98 and its 200 day moving average is $17.07. Kenvue has a 52-week low of $14.02 and a 52-week high of $25.17.

Kenvue (NYSE:KVUE) last released its earnings results on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.22 by $0.05. The company had revenue of $3.78 billion during the quarter, compared to analysts’ expectations of $3.68 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The business’s revenue was up 3.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.26 EPS. Equities analysts anticipate that Kenvue will post 1.14 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of KVUE. Salomon & Ludwin LLC bought a new position in shares of Kenvue in the third quarter worth $25,000. NBT Bank N A NY grew its stake in shares of Kenvue by 180.3% in the third quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after purchasing an additional 1,006 shares in the last quarter. Cornerstone Planning Group LLC grew its stake in shares of Kenvue by 705.2% in the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after purchasing an additional 1,361 shares in the last quarter. Physician Wealth Advisors Inc. boosted its stake in Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after buying an additional 618 shares in the last quarter. Finally, Elyxium Wealth LLC bought a new position in Kenvue during the fourth quarter valued at about $26,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.